Saturday, 2 August 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 02 August 2025
News

Injectable emerges as tough rival

Posted 29 July 2025 AM

A new weekly injectable for Parkinson’s disease in early development at the University of South Australia (UniSA) could prove a tough rival for companies in the space, if successfully commercialised.

The scientists have developed a sustained release formulation of levodopa and carbidopa – two key medications for Parkinson’s – that is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.